Peizer Terren S 的 Form 4 申報
Biovie Inc.BIVI,2022/8/26 申報
- 申報編號
- 0001520138-22-000381
- 申報時間
- 2022/8/26 17:10 ET
- 交易日
- 2018/7/3-2021/6/10
- 申報延遲
- 1,515 天遲報
- 10b5-1 計畫
- 表單沒有這欄(2023 年以前)
這份申報列了 9 筆非衍生性交易、10 筆衍生性交易。交易後 1515 天才申報,超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Peizer Terren SCIK 0000904534 | 董事、持股 10% 以上大股東 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2018/8/13 | Common Stock | C轉換取得 | +1,600,000 | –F1 | – | 1,600,000 | 間接 | |
| 2019/1/2 | Common Stock | A公司授予取得 | +1,600 | $0.00 | $0 | 1,601,600 | 直接 | |
| 2019/6/24 | Common Stock | A公司授予取得 | +1,526,334 | $45.00 | +$68,685,030 | 3,127,934 | 間接 | |
| 2019/9/24 | Common Stock | A公司授予取得 | +1,125,000 | –F6 | – | 4,252,934 | 間接 | |
| 2020/1/2 | Common Stock | A公司授予取得 | +4,422 | –F7 | – | 4,257,356 | 間接 | |
| 2020/1/2 | Common Stock | A公司授予取得 | +1,600 | $0.00 | $0 | 4,258,956 | 直接 | |
| 2020/9/22 | Common Stock | A公司授予取得 | +5,359,832 | –F8 | – | 9,618,788 | 間接 | |
| 2020/9/22 | Common Stock | M行使選擇權取得 | +1,549,750 | $0.0001 | +$154.98 | 11,168,538 | 間接 | |
| 2021/6/10 | Common Stock | A公司授予取得 | +8,361,308 | –F9 | – | 19,529,846 | 間接 |
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2018/7/3 | Common Stock | P買進取得 | +1,600,000 | –F10 | – | 1,600,000 | 間接 | |
| 2018/7/3 | Common Stock | P買進取得 | +1,713,331 | –F10 | – | 1,713,331 | 間接 | |
| 2018/8/3 | Common Stock | C轉換處分 | −1,600,000 | –F10 | – | 0 | 間接 | |
| 2019/6/24 | Common Stock | D交回公司處分 | −1,713,331 | –F5 | – | 0 | 間接 | |
| 2019/9/24 | 10% Convertible Debenture due 2020 | A公司授予取得 | – | –F6 | – | – | 間接 | |
| 2019/9/24 | Common Stock | A公司授予取得 | +1,250,000 | –F6 | – | 1,250,000 | 間接 | |
| 2020/7/13 | Common Stock | A公司授予取得 | +299,750 | –F6 | – | 299,750 | 間接 | |
| 2020/9/22 | 10% Convertible Debenture due 2020 | D交回公司處分 | – | $0.00 | – | 0 | 間接 | |
| 2020/9/22 | Common Stock | M行使選擇權處分 | −1,250,000 | –F8 | – | 0 | 間接 | |
| 2020/9/22 | Common Stock | M行使選擇權處分 | −299,750 | –F8 | – | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
See Exhibit 99.1
表 I 有 1 筆交易的價格引用這則附註。
- F5
Pursuant to a letter agreement with the Issuer dated June 24, 2019, Acuitas agreed to modify its existing rights under the 2018 SPA and agreed to immediately exchange the 2018 Warrants such that it effectively exercised its warrant in full pursuant to a cashless exercise thereof at an assumed then-current market price of $45 per share (adjusted to reflect the Reverse Stock Split) and, as a result, received an aggregate of 95% of the shares covered thereby.
表 II 有 1 筆交易的價格引用這則附註。
- F6
See Exhibit 99.1
表 I 有 1 筆、表 II 有 3 筆交易的價格引用這則附註。
- F7
The Issuer paid $13,487 of accrued interest on the Debenture through the issuance of 4,422 shares of the Issuer's common stock to Acuitas.
表 I 有 1 筆交易的價格引用這則附註。
- F8
See Exhibit 99.1
表 I 有 1 筆、表 II 有 2 筆交易的價格引用這則附註。
- F9
The Issuer issued these shares to NeurMedix, Inc. ("NeurMedix") in partial consideration for the acquisition of certain assets from NeurMedix and the assumption of certain liabilities of NeurMedix pursuant to the Asset Purchase Agreement, dated April 27, 2021, by and among the Issuer, NeurMedix, Inc. and Acuitas. In connection with the closing, NeurMedix assigned the rights to receive such shares to Acuitas.
表 I 有 1 筆交易的價格引用這則附註。
- F10
See Exhibit 99.1
表 II 有 3 筆交易的價格引用這則附註。
備註
Exhibit 99.1 - Explanation of Responses